K5 polysaccharides inhibit SARS-CoV-2 infection by preventing spike-proteolytic priming

SARS-CoV-2 spike glycoprotein is a promising drug target due to its crucial role in viral infection. Heparin, a long linear polysaccharide that inhibits SARS-CoV-2 infection by acting on spike, has limited antiviral applications due to its anticoagulant effect. E. coli K5 polysaccharides share the same structure as the heparin precursor and can be chemically modified to be devoid of anticoagulant activity. Here, biochemical assays and computer simulations reveal that K5 with high degree of sulfation at O- (K5OSH) or N- and O-positions (K5NOSH) bind spike with higher affinity than heparin, preventing its binding to ACE2 and furin cleavage. This mechanism is supported by cell syncytia assays showing that K5OSH and K5NOSH inhibit viral infection by blocking membrane fusion. Infection assays for SARS-CoV-2 Wuhan-Hu-1 and Omicron BA.1 variants corroborate their antiviral activity. These results support the therapeutic potential of K5OSH and K5NOSH against SARS-CoV-2, with K5OSH displaying more promising activity profile.

Authors

Institutions

Publication Details

Journal
npj Viruses
Published
2026-01-09
DOI
https://doi.org/10.1038/s44298-025-00163-4
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

K5 polysaccharides inhibit SARS-CoV-2 infection by preventing spike-proteolytic priming

Alberto Zani, Rebecca C. Wade, Giulia Paiardi, Maria Milanesi et al.
npj Viruses
SARS-CoV-2 and COVID-19 Research
article

K5 polysaccharides inhibit SARS-CoV-2 infection by preventing spike-proteolytic priming

Alberto Zani, Rebecca C. Wade, Giulia Paiardi, Maria Milanesi, Marco Rusnati, Liv Zimmermann, Vibor Laketa, Chiara Urbinati, Francesca Caccuri, Petr Chlanda, Arnaldo Caruso, Pasqua Oreste
article en

Abstract

SARS-CoV-2 spike glycoprotein is a promising drug target due to its crucial role in viral infection. Heparin, a long linear polysaccharide that inhibits SARS-CoV-2 infection by acting on spike, has limited antiviral applications due to its anticoagulant effect. E. coli K5 polysaccharides share the same structure as the heparin precursor and can be chemically modified to be devoid of anticoagulant activity. Here, biochemical assays and computer simulations reveal that K5 with high degree of sulfation at O- (K5OSH) or N- and O-positions (K5NOSH) bind spike with higher affinity than heparin, preventing its binding to ACE2 and furin cleavage. This mechanism is supported by cell syncytia assays showing that K5OSH and K5NOSH inhibit viral infection by blocking membrane fusion. Infection assays for SARS-CoV-2 Wuhan-Hu-1 and Omicron BA.1 variants corroborate their antiviral activity. These results support the therapeutic potential of K5OSH and K5NOSH against SARS-CoV-2, with K5OSH displaying more promising activity profile.

npj VirusesVol. 4(1)
University of Milan (IT), Heidelberg University (DE), University Hospital Heidelberg (DE), German Center for Infection Research (DE), Consorzio Interuniversitario per le Biotecnologie (IT), DKFZ-ZMBH Alliance (DE), Heidelberg Institute for Theoretical Studies (DE), University of Brescia (IT), Heidelberg University (US)
Joachim Herz Stiftung, Deutsches Zentrum für Infektionsforschung, European Commission, Deutsche Forschungsgemeinschaft, Ministero dell’Istruzione, dell’Università e della Ricerca, Klaus Tschira Stiftung
Openalex Percentile: Top 95%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.